论文部分内容阅读
美国宝洁公司(Procter & Gamble)和日本田边制药公司近日宣布,为推动试验性抗心率失常药物治疗,宝洁公司新药Azimilide将大部分亚洲市场全面推出,两家公司将在数月内对双方临时合同进行最后谈判。 由宝洁公司开发的新药Azimilide是一种抗心律失常药(治疗快速而紊乱的心跳)。它的药理作用是同时阻断钾离于的快通道和慢通道。这些钾离子通道能影响心率。目前
Procter & Gamble and Japan’s Tanabe Pharmaceuticals recently announced that Procter & Gamble’s new drug, Azimilide, will be fully launched in most of the Asian markets for the promotion of experimental anti-arrhythmia drugs. The two companies will intervene on both sides for several months. The contract is finalized. Azimilide, a new drug developed by Procter & Gamble, is an anti-arrhythmic drug (treating a rapid and disturbed heartbeat). Its pharmacological action is to block the fast and slow passage of potassium. These potassium channels can affect heart rate. Currently